MGTX News and Press, MeiraGTx Holdings plc From 01/27/22

-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and C...

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m....

MeiraGTx Holdings (NASDAQ:MGTX) reports that preliminary data on a phase 1 trial of AAV-haQP1 for Grade 2/3 radiation-inducted xerostomia (dry mouth) showed the candidate led to clinically meaningful improvement in symptoms and disease burden. Six of seven participants demonstrated improvemen...

Clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome (PRO) measures 6 of the 7 participants through 90-day assessments following treatment achieved clinically meaningful improvement in symptoms using both...

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUA...

MeiraGTx (NASDAQ:MGTX): Q3 GAAP EPS of -$0.59 misses by $0.08. Revenue of $6.94M (+36.1% Y/Y) beats by $4.54M. cash and cash equivalents of approximately $143.6M Press Release For further details see: MeiraGTx EPS misses by $0.08, beats on revenue

LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progres...

LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the followi...

Magenta Therapeutics (NASDAQ:MGTX) disclosed positive topline data from a Phase 2 trial for MGTA-145 stem cell mobilization in multiple myeloma. The investigator-initiated study was designed with the primary endpoint of mobilization and collection of 2M CD34+ stem cells per kg in up to t...

I covered MGTX in January, but didn't buy the stock. The stock has appreciated considerably since, but mainly due to a Barron's mention. The company has attractive technology. For further details see: MeiraGTx: Novel Riboswitch Technology Could Add Value